Singular focus on Bittensor (TAO), the leading AI token by
adoption and market capitalization
James Altucher to lead TAO token strategy initiatives
Planned initial acquisition of $10 million in TAO equates to over two times the Company's
current market capitalization; total acquisition target of $100 million
Know Labs, Inc. (NYSE American: KNW ("Know Labs" or the "Company"), a technology innovator specializing in non-invasive health monitoring solutions, today announced that it has entered into an agreement with Goldeneye 1995 LLC ("Buyer"), an affiliate of fintech investor, entrepreneur, and former Ripple Chief Risk Officer, Greg Kidd, to acquire a controlling interest in the Company. Upon the closing of the transaction, Mr. Kidd will become Chief Executive Officer and Chairman of the Board of Directors of the Company.
Under the terms of the agreement, the Buyer will acquire that number of shares of the Company’s common stock obtained by dividing (i) the sum of 1,000 Bitcoin and a cash sum to retire existing debt, redeem outstanding preferred equity and provide additional working capital, by (ii) the per share purchase price of $0.335. The Bitcoin will be employed by the Company’s treasury strategy, providing investors with significant economic exposure to this highly attractive digital asset.
https://finance.yahoo.com/news/greg-kidd-acquire-controlling-interest-130000334.html
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with high cholesterol.
Merck evaluated the candidate in two studies, including the CORALreef HeFH trial of patients with heterozygous familial hypercholesterolemia who had suffered from, or had a risk of, atherosclerotic cardiovascular disease and were being treated with a statin. The trial hit its primary endpoint of showing a clinically meaningful reduction in baseline levels of low-density lipoprotein cholesterol (LDL-C) at Week 24 compared to placebo, Merck explained in a June 9 release.
When it came to the CORALreef AddOn study of hypercholesterolemia patients, the study also hit its key endpoint of showing a reduction in LDL-C at Week 8 compared to the approved non-statin cholesterol medicines ezetimibe or bempedoic acid.
Merck didn’t divulge any detailed data behind the wins, only noting that there were “no clinically meaningful differences in incidences of adverse events” in either trial. The two studies form part of the company’s wider CORALreef development program, which spans 17,000 patients in total and also includes the ongoing CORALreef Lipids and CORALreef Outcomes phase 3 trials.
The hypercholesterolemia market is currently dominated by injectable PCSK9 inhibitors in the form of Amgen’s Repatha and Sanofi-Regeneron’s Praluent. Meanwhile, Novartis’ Leqvio uses small-interfering RNA technology to decrease PCSK9 production in the liver.
Enlicitide uses the same mechanism as approved monoclonal antibody injectable PCSK9 inhibitors but would give patients an oral alternative, potentially making it more attractive in terms of administration.
Today’s double win keeps Merck ahead of its rival AstraZeneca when it comes to getting the first oral PCSK9 inhibitor to regulators. The British-based pharma’s option is AZD0780, which was shown to halve cholesterol in a phase 2 dyslipidemia study in March.
“We are thrilled to bring forward the first phase 3 results from our clinical development program evaluating enlicitide, which, if approved, would be the first marketed oral PCSK9 inhibitor in the U.S.,” Dean Li, M.D., Ph.D., president of Merck Research Laboratories, said in the release.
“Enlicitide is a novel macrocyclic peptide that has the potential to deliver antibody-like efficacy and specificity for the validated PCSK9 mechanism in the form of a daily oral pill,” Li added. “We are working with urgency to make this oral therapy available to patients worldwide.”
Citi analysts described this morning’s data as “encouraging” ahead of an anticipated approval in 2027.
“We believe enlicitide could be a key player in the hyperlipidemia space, where an oral administration along with a positive efficacy and safety profile could be differentiating,” the analysts wrote in a June 9 note.
Caris Life Sciences, which offers an AI-powered precision medicine platform focused on oncology, announced terms for its IPO on Monday.
The Irving, TX-based company plans to raise $400 million by offering 23.5 million shares at a price range of $16 to $18. Certain investors intend to purchase $75 million worth of shares in the offering (19% of the deal). At the midpoint of the proposed range, Caris Life Sciences would command a fully diluted market value of $5.2 billion.
The company is developing and commercializing a platform meant to incorporate next-generation sequencing, artificial intelligence, and machine learning technologies to develop precision medicine diagnostic solutions meant to treat cancer. Caris Life Sciences states that its platform is based off of a data set with more than 6.5 million tests, run on over 849,000 cases, and has generated measurements of over 38 billion molecular markers. Its current commercial product portfolio is focused on oncology and consists of MI Profile, a tissue-based molecular profiling solution that has generated the majority of its revenue to date, and Caris Assure, a blood-based molecular profiling solution that was broadly launched in the first quarter of 2024 for therapy selection.
Caris Life Sciences was founded in 2008 and booked $452 million in revenue for the 12 months ended March 31, 2025. It plans to list on the Nasdaq under the symbol CAI. BofA Securities, J.P. Morgan, Goldman Sachs, Citi, TD Cowen, Evercore ISI, and Guggenheim Securities are the joint bookrunners on the deal. It is expected to price during the week of June 16, 2025.
Sanofi (SNY) is making strategic moves to enhance its position in the pharmaceutical market. In collaboration with AstraZeneca, the company is preparing for the early Q3 shipment of Beyfortus, its infant RSV protection therapy. This initiative is aimed at ensuring the treatment's widespread availability by the 2025-2026 RSV season. The companies have significantly ramped up their production capabilities to cater to the rising demand for this important therapy.
https://www.gurufocus.com/news/2914548/sanofi-sny-expands-beyfortus-production-ahead-of-rsv-season
CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its plant-derived, Type I recombinant human collagen (rhCollagen) for tissue regeneration and medical aesthetics, today announced the expansion of its agreement with STEMCELL Technologies, a biotechnology company that develops and supplies specialized cell culture media, tools, and services to support research in stem cell biology, regenerative medicine, immunology, and related life sciences. The amended agreement broadens the use of CollPlant's rhCollagen, extending beyond research applications to include clinical development and commercial-scale manufacturing.
